Search
Winners of the 2019 European PRRS Research Award
Winners of the 2019 European PRRS Research Award announced.
FRONTLINE becomes Brand of the Year 2019-2020
FRONTLINE becomes ‘Brand of the Year’ 2019-2020 in World Branding Awards
The chronic nature of generalized pustular psoriasis
Understanding the impact of the physical and psychological symptoms of this chronic disease.
New study paves the way for liver cirrhosis treatments
The ADVANCE study will be the most detailed observational study of its kind providing a detailed analysis of liver health.
trust-through-transparency
Transparency is an essential cornerstone of trust in the healthcare industry
World Veterinary Day aspects veterinary profession
• World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated.
MORE GREEN: Reducing emissions throughout the supply chain
How Thermo Fisher is contributing to the decarbonization of Boehringer Ingelheim’s supply chain by reducing their own emissions
The big, the bold, and the few
In the animal health industry, fewer players are vying for bigger market shares. What does that mean for companies, veterinarians, and consumers?
Liu
Hear Liu share his experience of being diagnosed with type 2 diabetes and heart disease on the same day and the impact this simultaneous diagnosis has had on his life as he knew it.
More Potential Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU
Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
The Unwearable Collection - The GPP patient experience
The Unwearable Collection™ is a fashion line based on the experiences of patients living with generalized pustular psoriasis, designed by Bart Hess.
Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Partnership-with-clicktherapeutics
Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia
vet scholars symposium
Veterinary students and researchers from 38 veterinary schools in North America and Europe gathered at the NIH in August to discuss the future of veterinary medicine.
Gerhard Kraus, Global Head of IT Infrastructure
Gerhard Kraus, Global Head of IT Infrastructure "Improving the health of humans and animals is our vision. What we do can make a huge impact"
Stem cell therapy for tendon and ligament injuries in horses
A tendon or ligament injury can be devastating for horse owners, riders and trainers. Our new stem cell product improves the quality of healing.
New treatment for chronic kidney disease approved in the EU
The European Commission (EC) has approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease
Reggie the Red Blood Cell
Join Reggie, our curious red blood cell, on a journey exploring connections between the heart, kidneys and pancreas.
GastroGard the first imported equine drug in China
GastroGard® approved as the first imported equine drug in China. Boehringer Ingelheim officially starts equine health business in China.
Generalized pustular psoriasis: Value of community support
Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the importance of knowledge sharing, community support and challenges faced by those living with GPP.
History of Cats
From the African wildcat to the domesticated house cat of today, the fascinating journey and history of the cat touches almost all corners of the world.
Pulmonary Fibrosis: Early discovery makes all the difference
Video taking a deep dive into pulmonary fibrosis. Visit an underwater world that brings to life the physical change PF has on the lungs.
Boehringer Ingelheim acquires Nerio Therapeutics
Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics